Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Why United Continental Earnings Are Taking Off

11m 247wallst
When United Continental Holdings Inc. (NYSE: UAL) reported its most recent quarterly results after the markets closed on Tuesday, the airline operator said that it had $3.23 in earnings per share (EPS) and $10.78 billion in revenue. The consensus estimates had called for $3.06 in EPS and $10.72 billion in revenue, and it the second quarter of last year, EPS were $2.75 and revenue at $10.0 billion.
UAL

15
United Continental (UAL) Beats on Q2 Earnings, Raises View

1h zacks
United Continental Holdings, Inc. (UAL - Free Report) reported better-than-expected results in the second quarter of 2018. The company’s earnings (excluding 75 cents from non-recurring items) of $3.23 per share surpassed the Zacks Consensus Estimate of $3.07. The bottom line also increased 17% year over year owing to higher revenues.
GEC GE SKYW JBLU GNE UAL ALGT

0
United Continental Holdings (UAL) Shares Pop on Earnings Beat

16h investorplace
United Continental Holdings (NYSE:UAL) reported its latest quarterly earnings results after the bell Tuesday, posting an adjusted earnings beat that sent shares rising late in the day.
UAL

15
Even at $4 Per Share, Gogo Won’t Make You Dough

21h investorplace
Gogo (NASDAQ:GOGO) has gotten absolutely pulverized over the past year. From a high of $14 per share last September, investors have dumped GOGO stock all the way down into the high $3s today. Even at this huge discount, however, GOGO stock is far from an attractive bet.
VSAT MS.PRI ENT MS.PRK MS.PRE MS.PRF MS.PRG GOGO MS UAL MS.PRA ENTWW

8
U.S. stocks turn higher with Powell testimony, earnings in focus - MarketWatch

22h marketwatch
U.S. stock rose in morning trading on Tuesday, recovering from an earlier decline after Federal Reserve Chairman Jerome Powell indicated the U.S. central bank wouldn’t move too quickly in changing monetary policy, and that it would be flexible in the face of changing conditions.
JBK GS.PRICL GSC TFG GS.PRB GS.PRA NFLX UAL GSJ GS.PRJ GS.PRI GS GLSSP GS.PRD GS.PRC CSX GJS GS.PRN UNH GS.PRK

0
What to Expect From United Continental Earnings

22h 247wallst
United Continental Holdings Inc. (NYSE: UAL) is scheduled to release its second-quarter financial results after the markets close on Tuesday. The consensus estimates from Thomson Reuters are $3.06 in earnings per share (EPS) and $10.72 billion in revenue. The same period of last year reportedly had $2.75 in EPS and $10.00 billion in revenue.
TRI UAL

0
J. B. Hunt's (JBHT) Q2 Earnings Surpass Estimates, Rise Y/Y

2018-07-16 zacks
J.B. Hunt Transport Services, Inc. (JBHT - Free Report) performed impressively in the second quarter of 2018, reporting better-than-expected revenues and earnings per share. Both the metrics also improved on a year-over-year basis.
UNP SKYW UAL

0
UAL / United Continental Holdings, Inc. 8-K (Current Report)

2018-07-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
UAL

0
UAL / United Continental Holdings, Inc. 8-K (Current Report)

2018-07-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
UAL

73
H-B-Oh No!

2018-07-15 seekingalpha
From the age of 25–40, my range of emotions could generously be described as “narrow.” I loved nobody, and the only real emotions I felt were satisfaction or disappointment from my ambition as I howled in the money storm. My approach to life could best be summarized as “I want more, f***ing more.” Problem is, “more” started getting harder to define. During that 15-year period, I laughed out loud a lot less than before and didn’t cry once.
FB TM AAL TWX JBLU NFLX SAVE GOOG UAL TWC AMZN T GOOGL VZ DAL DIS

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to UAL / United Continental Holdings, Inc. on message board site Silicon Investor.

Qualcomm Moderated Thread - please read rules before posting The New Qualcomm - write what you like thread.
Qualcomm Incorporated (QCOM) The New QUALCOMM - Coming Into Buy Range
Virtual Reality Genomic Health: predicting the course of an individualu0027s can
Vanguard Mutual Funds Actual left/right wing discussion
Vanuard Mutual Funds CDMA, Qualcomm, [Hong Kong, Korea, LA] THE MARKET TEST!
CUSIP: 910047109